Clinical trial · no report yet · Phase 2
CLARINET FORTE
Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg
- NCT02651987 ↗
- Completed
- Ipsen
- 15 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 8 | |
| Podcasts | 5 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- Efficacy and Safety of Lanreotide Autogel® 120 mg Administered Every 14 Days in Well Differentiated, Metastatic or Locally Advanced, Unresectable Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg Administered Every 28 Days
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Pancreatic Tumours; Midgut Neuroendocrine Tumours
- Interventions
- Lanreotide autogel 120 mg
- Arms
- Lanreotide Autogel® · Experimental
- Enrollment
- 99
- Primary outcomes
- Median Progression Free Survival (PFS)
- Sponsor
- Ipsen
- Start
- Dec 15, 2015
- Primary completion
- Oct 16, 2019
- Results posted
- Yes
- Registry record
- NCT02651987 · updated Oct 3, 2022